Pms69 - Biosimilar and Originator Infliximab: Influence of Local Policy Measures and Practices on Market Dynamics Between Swedish Counties

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1783
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pms70 - Biosimilar and Originator Etanercept: Influence of Local Policy Measures and Practices on Market Dynamics Between Swedish Counties

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Influence of Biosimilar Infliximab Launch on the Utilization Pattern of Biological Medicines: The Case of Hungary

Expert Review of Pharmacoeconomics and Outcomes Research
MedicineHealth PolicyPharmacology
2019English

PF-06438179/GP1111: An Infliximab Biosimilar

BioDrugs
MedicineBiotechnologyPharmacology
2018English

Efficacious Transition From Reference Infliximab to Biosimilar Infliximab in Clinical Practice

International Journal of Rheumatic Diseases
Rheumatology
2019English

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study

BioDrugs
MedicineBiotechnologyPharmacology
2018English

Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar

BioDrugs
MedicineBiotechnologyPharmacology
2019English

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition

JAMA network open
Medicine
2019English

Influence of the Exogenous Factors on the Market Policy

International conference KNOWLEDGE-BASED ORGANIZATION
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy